Oruka Therapeutics, Inc. (NASDAQ:ORKA) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $133.00.

ORKA has been the subject of several analyst reports. Wedbush reissued an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. Mizuho set a $120.00 price objective on shares of Oruka Therapeutics in a report on Thursday, September 3rd. HC Wainwright restated a “buy” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 27th. BTIG Research reissued a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research report on Monday, October 19th. Finally, Piper Sandler restated an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th.

Oruka Therapeutics Trading Up 7.1%

NASDAQ ORKA opened at $102.86 on Monday. Oruka Therapeutics has a 12 month low of $25.23 and a 12 month high of $115.51. The company’s 50 day simple moving average is $88.22 and its 200 day simple moving average is $70.57.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, sell-side analysts anticipate that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

Insider Activity at Oruka Therapeutics

In other news, CEO Lawrence Klein sold 75,000 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total value of $6,887,250.00. Following the completion of the sale, the chief executive officer owned 925,580 shares of the company’s stock, valued at $84,996,011.40. This represents a 7.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total value of $734,143.86. Following the transaction, the insider directly owned 31,771 shares in the company, valued at $2,935,004.98. This trade represents a 20.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 179,950 shares of company stock valued at $16,492,680 in the last ninety days. Corporate insiders own 23.49% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of Oruka Therapeutics in the 2nd quarter worth about $474,916,000. Remedium Capital Partners LLC lifted its position in shares of Oruka Therapeutics by 0.9% during the first quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock worth $76,796,000 after purchasing an additional 13,247 shares during the last quarter. Jupiter Topco LLC purchased a new position in Oruka Therapeutics in the 2nd quarter worth about $130,968,000. Avidity Partners Management LP increased its holdings in shares of Oruka Therapeutics by 15.1% during the 1st quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after purchasing an additional 100,000 shares during the period. Finally, Candriam S.C.A. grew its stake in shares of Oruka Therapeutics by 2.6% during the first quarter. Candriam S.C.A. now owns 411,006 shares of the company’s stock worth $20,160,000 after purchasing an additional 10,497 shares during the period. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.